AnaptysBio (ANAB) to Release Earnings on Thursday

AnaptysBio (NASDAQ:ANAB - Get Free Report) is expected to announce its Q1 2025 earnings results before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($1.30) per share and revenue of $15.27 million for the quarter.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last posted its earnings results on Thursday, February 27th. The biotechnology company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.61) by $0.89. The firm had revenue of $43.11 million during the quarter, compared to analysts' expectations of $10.17 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. On average, analysts expect AnaptysBio to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

AnaptysBio Trading Down 2.4 %

Shares of NASDAQ ANAB traded down $0.51 during mid-day trading on Friday, reaching $21.19. 294,391 shares of the company's stock were exchanged, compared to its average volume of 591,002. The business has a fifty day simple moving average of $18.24 and a 200 day simple moving average of $19.23. AnaptysBio has a twelve month low of $12.21 and a twelve month high of $41.31. The firm has a market capitalization of $626.67 million, a price-to-earnings ratio of -3.49 and a beta of -0.20.

AnaptysBio declared that its board has authorized a stock buyback plan on Monday, March 24th that authorizes the company to repurchase $75.00 million in shares. This repurchase authorization authorizes the biotechnology company to buy up to 13.1% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company's leadership believes its shares are undervalued.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Wedbush reaffirmed an "outperform" rating and issued a $40.00 price objective on shares of AnaptysBio in a research report on Thursday. HC Wainwright reaffirmed a "neutral" rating and set a $22.00 price objective on shares of AnaptysBio in a research report on Tuesday, March 4th. Johnson Rice reiterated a "buy" rating on shares of AnaptysBio in a report on Wednesday, March 26th. Guggenheim restated a "buy" rating on shares of AnaptysBio in a research note on Monday, March 3rd. Finally, JPMorgan Chase & Co. raised their price target on shares of AnaptysBio from $36.00 to $42.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. Four analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $33.63.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.